Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and platinum-refractory epithelial ovarian cancer (EOC). Preliminary results of a Phase I dose-escalat

Presented at EORTC 2014, Barcelona, Spain

C Le Tourneau (1), I Ray-Coquard (2), N Isambert (3), C Gomez-Roca (4), P Cassier (2), MP Sablin (1), E Rouits (5), B Gavillet (5), C Zanna (5), P Fumoleau (3), JP Delord (4).

(1) Institut Curie, Paris, France

(2) Centre Léon Bérrard, Lyon, France

(3) Centre Georges-Francois Leclerc, Dijon, France

(4) Centre Claudius Regaud, Toulouse, France

(5) Debiopharm International SA, Lausanne, Switzerland